In a report released today, Ram Selvaraju from H.C. Wainwright initiated coverage with a Buy rating on Timber Pharmaceuticals (TMBR – Research Report) and a price target of $2.00. The company's shares closed last Wednesday at $0.39, close to its 52-week low of $0.24. According to TipRanks.com, Selvaraju 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -27.1% and a 24.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Oncternal Therapeutics, and Oramed Pharmaceuticals. Timber Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-initiates-a-buy-rating-on-timber-pharmaceuticals-tmbr?utm_source=advfn.com&utm_medium=referral